Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
2상
완료
NCT05605301
| 대상 질환 | Epilepsy; Seizure |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | University of Virginia |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 9 명 |
|---|
| 중재(약물) | Oral 2-Deoxy-D-Glucose (2DG) |
|---|
| 시작일 | 2022년 9월 2일 |
|---|
| 완료일 | 2024년 2월 5일 |
|---|
| 결과 공개일 | 2026년 6월 9일 |
|---|
요약
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use. This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg
Area Under the Curve From Time Zero to Last Observed Time Point (AUClast)
From time of drug administration until 24 hours post-dose · hour*ug/mL
| 2DG 40 mg Single Dose | 2.81 ± 0.49 hour*ug/mL |
|---|
| 2DG 60 mg Single Dose | 2.93 ± 1.13 hour*ug/mL |
|---|
| 2DG 60 mg Twice Daily | 4.16 ± 0.57 hour*ug/mL |
|---|
Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf)
From time of drug administration until 24 hours post-dose · hr*ug/mL
| 2DG 40 mg Single Dose | 3.56 ± NA hr*ug/mL |
|---|
| 2DG 60 mg Single Dose | 3.19 ± 1.59 hr*ug/mL |
|---|
| 2DG 60 mg Twice Daily | 4.71 ± 0.81 hr*ug/mL |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.